TriangleQuisinostat (NCT06932757)
Quisinostat trial for Uveal Melanoma (NCT06932757). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for patients aged nineteen or older with class-two, high-risk uveal melanoma by gene-expression testing, treated locally within 183 days. The tumor must measure at least twelve millimeters across; metastatic disease is excluded.
The idea: quisinostat inhibits HDAC enzymes involved in gene regulation. Patients take twelve milligrams orally three times weekly for up to seventeen three-week cycles. Researchers measure survival without distant spread. Prior adjuvant treatment or HDAC inhibitors exclude participation.
This phase 2 study plans 63 patients. Jose Lutzky leads at the University of Miami, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.